July 13, 2016 News by InĆŖs Martins, PhD Side Effects and Convenience of MS Therapies Seen to Determine Patients’ Adherence to Them Despite the existence of several disease-modifying drugs for peopleĀ with relapsing-remitting multiple sclerosis (RRMS), patients’ satisfaction plays a critical role in their adherence to treatment. ImprovingĀ adherence should be a major concernĀ in the clinicĀ to prevent patients from evolving to more debilitating stages of the disease. AĀ team of researchers in Germany reportĀ that side…
June 27, 2016 News by Patricia Inacio, PhD Vitamin D Levels Seen to Predict Relapse Rates Only in Younger MS Patients A retrospective study of vitamin DĀ status andĀ disabilityĀ progression in multiple sclerosis patients āĀ using real-life, clinical data from a large and varied group ā found no Ā correlation between the two, althoughĀ vitamin D levels may predict the occurrence ofĀ relapses in some patients. But these findingsĀ may haveĀ beenĀ limited by the lower doses of daily vitamin…
June 1, 2016 News by Patricia Silva, PhD #CMSC16 – MS Expert Fred Lublin Discusses Relevance of MS Relapses Dr. Fred Lublin,Ā a renowned multiple sclerosis (MS) expert atĀ Mount Sinai Medical Center, helped launch theĀ Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting,Ā June 1 – 4, in National Harbor, Md. with the John F. Kurtzke Memorial Lecture he titledĀ āDo Relapses Really Matter?ā āHow relapses influence disease worsening,…
May 23, 2016 News by InĆŖs Martins, PhD Relapses Prevented in Multiple Sclerosis Mouse Model Researchers at theĀ University of Heidelberg, Germany, recently showed that peripheral blood cells loaded with a drug that resembles the myelin protein are able to inhibit harmful immune responses and prevent relapses in a mouse model of relapsing-remitting multiple sclerosis (MS). The findings were described in the study “…
May 4, 2016 News by Patricia Silva, PhD Acthar Gel an Effective Treatment for MS Relapses at Lower Cost, Company Reports Clinical results presented at the recentĀ Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meetingĀ in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses is associated with beneficial outcomes.Ā The gel, according to its producer,Ā is also available at a lower price than other frequently used…
May 2, 2016 News by BioNews Staff #CMSC16 – An Interview with Dr. Fred Lublin of the Center for Multiple Sclerosis at Mount Sinai Dr. Fred Lublin, a neuroimmunologist with a specialty in experimental therapies, will open this year’s annual meeting of the Consortium of Multiple Sclerosis Centers on June 1 with an address questioning the continuing importance of relapses in multiple sclerosis (MS). But the question raised by the title of the…
April 18, 2016 News by Patricia Silva, PhD #CMSC16 – Dr. Fred Lublin to Deliver Opening Lecture on MS Relapses and Their Impact on Patient Outcomes The Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting will open with the John F. Kurtzke Memorial Lecture,Ā āDo Relapses Really Matter?ā,Ā by the renowned multiple sclerosis (MS) expertĀ Dr. Fred D. Lublin of Mount Sinai Medical Center. The June 1 lectureĀ offers a fresh view on recent evidence intoĀ the impact…
April 13, 2016 News by admin Study Associates Obesity in Youth, Low Vitamin D Levels with MS Onset and Progression A systematic review of existing medical literature on multiple sclerosis (MS) could shed light on MS causes and predictors for diseaseĀ progression, and on lifestyle changes ā ranging from vitamin D intake to weight loss ā that might reduce a person’s risk. The report,Ā “Factors associated with onset, relapses…
January 22, 2016 News by Patricia Silva, PhD EMD Serono Gains Exclusive US Rights to MS Drug for Relapsing Forms of Disease EMD Serono, theĀ North American biopharmaceutical business arm of Merck, announced it has gained exclusive rights over RebifĀ (interferon beta-1a) inĀ the United States. RebifĀ Ā is a treatment for relapsing forms of multiple sclerosis (MS). Rebif, an approved drug, is usedĀ to decrease the frequency of MS relapses and delay the occurrence of…
January 5, 2016 News by Patricia Silva, PhD Review Highlights Long List of Unmet Needs For MS Patients In a special feature publishedĀ in the journal American Health & Drug Benefits, authorsĀ Stanton R. Mehr, President of SM Health Communications, and Marj P. Zimmerman, President of RxDirections, discuss the many unmet medical needs multiple sclerosis (MS) patients still face in dealing with the…
November 30, 2015 News by Patricia Silva, PhD People with Relapsing NMOD Invited to Enter Phase 3 Study The National Multiple Sclerosis Society recently announced that a research team is recruiting 132 patients with a diagnosis of neuromyelitis optica spectrum disorders (NMOSD) for a Phase 3 clinical study comparing an experimental medicine with an inactive placebo. NMOSD is a rare disorder caused by immune system cells attacking…